Niraparib Tosylate Patent Expiration
Niraparib Tosylate is used for treating ovarian, fallopian tube, or primary peritoneal cancer associated with HRD positive status and recurrent ovarian or fallopian tube cancer with BRCA mutations. It was first introduced by Glaxosmithkline Llc
Niraparib Tosylate Patents
Given below is the list of patents protecting Niraparib Tosylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zejula | US11730725 | Niraparib formulations | Jan 25, 2039 | Glaxosmithkline |
| Zejula | US11091459 | Niraparib compositions | Mar 27, 2038 | Glaxosmithkline |
| Zejula | US11673877 | Niraparib compositions | Mar 27, 2038 | Glaxosmithkline |
| Zejula | US8859562 | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer | Aug 04, 2031 | Glaxosmithkline |
| Zejula | US8071623 | Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors | Mar 27, 2031 | Glaxosmithkline |
| Zejula | US8436185 | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide | Apr 24, 2029 | Glaxosmithkline |
| Zejula | US8071579 | DNA damage repair inhibitors for the treatment of cancer | Aug 12, 2027 | Glaxosmithkline |
| Zejula | US8143241 | DNA damage repair inhibitors for treatment of cancer | Aug 12, 2027 | Glaxosmithkline |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Niraparib Tosylate's patents.
Latest Legal Activities on Niraparib Tosylate's Patents
Given below is the list recent legal activities going on the following patents of Niraparib Tosylate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 13 Feb, 2024 | US11730725 |
| Mail Pet Dec Routed to Certificate of Corrections Branch | 12 Feb, 2024 | US11730725 |
| Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 12 Feb, 2024 | US11730725 |
| Pet Dec Routed to Certificate of Corrections Branch | 09 Feb, 2024 | US11730725 |
| Adjustment of PTA Calculation by PTO | 09 Feb, 2024 | US11730725 |
| Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 09 Feb, 2024 | US11730725 |
| Petition Entered | 13 Oct, 2023 | US11730725 |
| Recordation of Patent eGrant | 22 Aug, 2023 | US11730725 |
| Patent Issue Date Used in PTA Calculation Critical | 22 Aug, 2023 | US11730725 |
| Recordation of Patent Grant Mailed Critical | 22 Aug, 2023 | US11730725 |
Niraparib Tosylate's Family Patents
